Key Companies Covered in the Vasopressin for Vasoplegic Shock Market Research Report Are Endo International plc, AMOMED Pharma, La Jolla Pharmaceutical Company, Pfizer Inc., Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Eagle Pharmaceuticals, Inc. and other key market players

Pune, Nov. 04, 2020 (GLOBE NEWSWIRE) -- The global vasopressin for vasoplegic shock market size is expected to gain momentum by reaching USD 2,657.9 million by 2027, while exhibiting a stellar CAGR of 14.8% between 2020 and 2027. This is attributable to the increasing prevalence of cardiovascular surgeries that propels the demand for vasopressin for vasoplegic shock across the globe. The report further mentions that the market stood at USD 890.9 million in 2019. North America stood at USD 561.3 million in 2019 and is expected to hold the highest position in the global market in the forthcoming years.

Vasoplegia is a type of syndrome that involves pathologically low systemic vascular resistance. It further leads to reduced blood pressure amid presence of a raised cardiac output. The growing adoption of vasopressin for vasoplegic shock treatment is gaining popularity owing to its efficiency in treating the syndrome.

Industry Development:

• April 2018 – Eagle Pharmaceuticals, Inc announced the approval of its new drug application, ANDA for 1ml vasopressin injection. The product is a original generic version of Endo International plc’s Vasostrict formulation.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/vasopressin-for-vasoplegic-shock-market-104065

Rising Cardiac Syndrome Cases amid COVID-19 to Boost Growth

The recent spike in the cases of people suffering from the novel coronavirus disease is expected to surge the cardiac syndrome risk amongst people susceptible to contracting it.

This is leading the pharmaceutical sector to focus on developing advanced vasopressin drugs for treatment purposes. This is expected to bode well for the growth of the global market in the near future.

Click here to get the short-term and long-term impact of COVID-19 on this Market.
Please visit: https://www.fortunebusinessinsights.com/vasopressin-for-vasoplegic-shock-market-104065

DRIVING FACTORS

Increasing Incidence of Cardiovascular Surgeries to Augment Growth

According to the Centers for Disease Control and Prevention (CDC), every year about 340,000 Coronary Artery Bypass Grafting (CABG) procedures are performed in the U.S. The increasing number of cardiovascular surgeries propels the demand for vasopressin to control the blood flow.

Additionally, the growing number of CABG procedures and sepsis patients are boosting the demand for innovative vasopressin treatment options. This is expected to bode well for the global vasopressin for vasoplegic shock market growth during the forecast period.

Quick Buy -  Vasopressin for Vasoplegic Shock Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104065

SEGMENTATION

Post Cardiac Surgery Segment Held 25.2% in 2019

The post cardiac segment, based on application, held a market share of about 25.2% in 2019 and is likely to gain momentum owing to the increasing number of cardiac surgeries that require efficient post-cardiac treatment globally.

REGIONAL INSIGHTS

Increasing Prevalence of Sepsis in North America to Favor Growth

Among all the regions, North America stood at USD 561.3 million in 2019 and is expected to hold the highest position in the global market in the forthcoming years. This is ascribable to the increasing prevalence of sepsis that drives the demand for advanced vasopressin for vasoplegic shock treatment procedures in the region.

The market in Europe is expected to experience a significant growth backed by surging investments in R&D by the government as well as major companies to develop advanced vasopressin for vasoplegic shock treatment between 2020 and 2027.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/vasopressin-for-vasoplegic-shock-market-104065

COMPETITIVE LANDSCAPE

Prominent Companies Focus on Investment in R&D Activities to Develop Innovative Vasopressin for Vasoplegic Shock

The global vasopressin for vasoplegic shock market is fragmented by the presence of key players that are focusing on raising investments to develop advanced vasopressin for vasoplegic shock treatment.

Additionally, the major companies are striving to maintain their presence in the global marketplace by adopting strategies such as partnership, collaboration, and merger and acquisition to gain a competitive edge over their rivals during the forecast period.

List of the Companies Profiled in the Vasopressin for Vasoplegic Shock Market:

• Endo International plc (Dublin, Ireland)
• AMOMED Pharma (Vienna, Austria)
• La Jolla Pharmaceutical Company (California, U.S.)
• Pfizer Inc. (New York, U.S.)
• Ferring Pharmaceuticals (Saint-Prex, Switzerland)
• Fresenius Kabi Canada (Toronto, Canada)
• Astellas Pharma (Tokyo, Japan)
• Eagle Pharmaceuticals, Inc. (New Jersey, U.S.)
• Others

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/vasopressin-for-vasoplegic-shock-market-104065

Table of Contents:

1.       Introduction
1.1.     Research Scope
1.2.     Market Segmentation
1.3.     Research Methodology
1.4.     Definitions and Assumptions
2.       Executive Summary
3.       Market Dynamics
3.1.     Market Drivers
3.2.     Market Restraints
3.3.     Market Opportunities
4.       Key Insights
4.1. Recent Industry Developments Such as Mergers & Acquisitions
4.2. Regulatory Scenario for Key Countries
4.3. New Product Launch
4.4. Statistics on Prevalence of Cardiac Disorders for Key Countries/Regions
4.5. Pipeline Analysis

5. Global Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027

5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Application
5.2.1. Sepsis
5.2.2. Post Cardiac Surgery
5.2.3. Others
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa

6. North America Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027

6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast - By Application
6.2.1. Sepsis
6.2.2. Post Cardiac Surgery
6.2.3. Others
6.3. Market Analysis, Insights and Forecast - By Country
6.3.1. U.S.
6.3.2. Canada

TOC Continued….!

Have a Look at Related Reports:

Cardiac Biomarkers Market Share & Industry Analysis, By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Biomarker (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2027

Asthma Treatment Market Share & Industry Analysis, By Treatment (Long-Term Control Medications, and Quick-Relief Medications), By Route of Administration (Injectable, Oral, and Inhaled), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2020-2027

Legionella Testing Market Share & Industry Analysis, By Type (Culture Media, Urine Antigen Testing (UAT), Polymerase Chain Reaction (PCR), Serology, and Direct Fluorescent Antibody (DFA) test; By End User (Hospitals & Clinics, Diagnostic Centers, and Others) and Regional Forecast, 2020-2027

Alopecia Treatment Market Share & Industry Analysis, By Route of Administration (Topical, Injectable, Oral), By Gender Type (Male, Female), By Age Group (Below 18 years, 18 - 34 Years, 35 - 49 Years, Above 50 Years), By End User and Regional Forecast, 2020-2027

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Share & Industry Analysis, By Disease Indication (Arthritis, Migraine, Ophthalmic Diseases, and Others), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/global-vasopressin-for-vasoplegic-shock-market-10295

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.